AA

Anil Agarwal

Director Director DIN 09193078
DIN 09193078 First appointment May 2021 Primary industry Life Sciences
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since May 2021
Shareholding value •••• Premium profile

About Anil Agarwal

Data last updated:

Anil Agarwal was a Director at Ras Life Sciences Private Limited (2021–2025) and Director at Biomerieux India Private Limited (2021–2025). The companies operate in Life Sciences and Healthcare.

DIN 09193078
Primary Designation Director
Industry Life Sciences
First Appointment 19 May 2021

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Ras Life Sciences Private Limited U33110DL2008PTC378612
Director16 Dec 20212008₹1.2 Lakh (FY 2022)Active
Biomerieux India Private Limited U85195DL1998PTC094403
Director19 May 20211998₹1,007 Cr (FY 2025)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Ras Life Sciences Private Limited
Biomerieux India Private Limited
Premium access

Shareholding and investment profile for Anil Agarwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anil Agarwal

Anil Agarwal was first appointed on 19 May 2021 as Director at Biomerieux India Private Limited.

Anil Agarwal held 2 earlier board appointments: Ras Life Sciences Private Limited (Director, 16 Dec 2021 to 01 Jan 2025); Biomerieux India Private Limited (Director, 19 May 2021 to 01 Jan 2025).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available